Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 16/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 13/20 | 0.43 |
| ▸ | CTSD | P07339 | 12/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3356554 | 0.89 | BACE1 (0.45) | BACE1BACE2CTSDRENKCNH2 | |
| SCHEMBL3359224 | 0.87 | BACE1 (0.34) | BACE1BACE2CTSDRENKCNH2 | |
| SCHEMBL3361382 | 0.83 | CTSD (0.35) | BACE1BACE2CTSDSLC6A4GCK | |
| SCHEMBL3360622 | 0.80 | BACE1 (0.35) | BACE1BACE2CTSDRENKCNH2 | |
| SCHEMBL3359205 | 0.79 | BACE1 (0.35) | BACE1BACE2CTSD | |
| SCHEMBL3243721 | 0.78 | GCK (0.33) | BACE1BACE2CTSDSLC6A4GCK | |
| SCHEMBL3635544 | 0.78 | BACE1 (0.53) | BACE1BACE2CTSDKCNH2 | |
| SCHEMBL3358481 | 0.78 | BACE1 (0.51) | BACE1BACE2CTSDRENKCNH2 | |
| SCHEMBL3360050 | 0.78 | BACE1 (0.35) | BACE1BACE2CTSDHSD11B1 | |
| SCHEMBL3358088 | 0.76 | BACE1 (0.40) | BACE1BACE2CTSDRENKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010056194-A1 | 5H-PYRROLO [ 3, 4-B] PYRIDIN DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | claimed |
| US-20100125081-A1 | NEW COMPOUNDS 574 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | claimed |
| WO-2010056194-A1 | 5H-PYRROLO [ 3, 4-B] PYRIDIN DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
| US-20100125081-A1 | NEW COMPOUNDS 574 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125081-A1 | NEW COMPOUNDS 574 | PSEN1, PSEN2, BACE1 | BACE1 3/4885BACE2 10/4885CTSD 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.